2025.12. 24 本文字数：1128，阅读时长大约2分钟 据央视财经，当地时间22日，美国马里兰州一个陪审团裁定，美国强生公司需向因使用其婴儿爽身 粉产品而罹患癌症的一名女子，支付约15.6亿美元（约合人民币110亿元）赔偿。 据悉，这名女子指控强生公司的婴儿爽身粉产品含有石棉，导致她患上间皮瘤。陪审团认为，强生公 司对未能警告原告其婴儿爽身粉含有石棉负有责任。 23日，强生公司表示将立即启动上诉程序。 据界面新闻，目前强生在淘宝的旗舰店所售婴儿爽身粉均标明采用天然玉米粉。 产品详情页显示，爽身粉0添加酒精、邻苯、二甲酸盐以及色素、尼泊金和防腐剂，玉米淀粉含量达 99%。其特别强调，爽身粉不含石棉类原料（吸水力差）、不含松科植物类原料（潜在致敏风 险）。 il. 物理加丁2公 直播中 0% 不含石棉 0% 不含松科类植物原料 图集 款式 款式 选择 北京市 200+人已买 多人评价"使用情况很好" 回头客33 3 开通省钱卡,领120元通用红包 干性肤质婴儿爽身粉热销榜第4名 (-2 券后 ¥ 20.05起 | 优惠前 ¥ 25.4起 已售 1万 + 淘金币可抵0.25元起|立减5.1元 天猫 强生婴儿 ...

Financial Performance - AbbVie reported adjusted diluted profits per share of $1.86 for the quarter and increased its full-year 2025 adjusted EPS outlook to a range of $10.61 to $10.65 [1] - The company achieved net revenues of $15.7 billion, representing a 9.1% year-over-year increase, driven by its immunology and neuroscience portfolios [3] - Adjusted diluted EPS of $2.80 grew 15.7% year-over-year, with management raising full-year 2025 guidance to approximately $10.85 at the midpoint [13] Dividend Policy - AbbVie has paid and increased dividends for the past 54 years, earning the title of a Dividend King, and announced a 5.5% dividend increase starting February 2026, raising the quarterly payout to $1.73 per share [1] - Since its inception in 2013, AbbVie has increased its dividend by more than 330%, showcasing its commitment to income-focused investors [1] - The company currently pays an attractive yield of 3.04%, significantly higher than the healthcare average of 1.6% [1] Revenue Growth by Segment - Neuroscience revenues increased by more than 20% to $2.841 billion, with key drugs like Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta showing strong growth [2] - The immunology portfolio generated $7.8 billion in quarterly revenue, a roughly 12% increase, with Skyrizi and Rinvoq leading the growth [3] - Skyrizi alone generated $4.7 billion in revenue, up over 47%, while Rinvoq grew by more than 35% to $2.18 billion [3] Market Performance - AbbVie stock has soared 29% year-to-date, outperforming the S&P 500 Index gain of 17.4% [4] - Wall Street analysts have assigned a "Moderate Buy" rating to AbbVie, with a mean target price of $245.84, indicating a potential upside of 7.8% from current levels [6]

欲览更多环球财经资讯，请移步7×24小时实时财经新闻 市场 12月24日收盘：美股收高科技股领涨 标普指数创历史新高 12月24日美股成交额前20：凯西伍德持续减持特斯拉 12月24日热门中概股涨跌不一 台积电涨1.27%，蔚来跌2.40% 贵金属集体大涨 黄金白银再刷历史新高 周二国际油价小幅上扬 市场关注供需前景 欧洲股市升至纪录新高 美国批准推动诺和诺德股价大涨 宏观 特朗普称美联储主席应在市场表现良好时降低利率 美国消费者信心连续第五个月下滑 就业看法更趋悲观 美国发布H-1B签证新规 以高薪申请人为优先 美国经济2025年第三季度增长4.3% 美联储主席候选人哈塞特：美国在降息方面已严重滞后 贝森特：美联储2%的通胀目标有商榷余地 或可设置为一个区间 美国议员起诉特朗普 指其未经国会批准将个人名字加到肯尼迪中心 特朗普政府将于明年1月起，扣押拖欠助学贷款借款人的薪资收入 美国最高法院驳回特朗普在芝加哥动用国民警卫队的请求 美国对格陵兰岛动作不断 北欧三国声援丹麦 美国向加勒比增派特战飞机和部队 加拿大央行不确定下一次政策利率调整会在何时以及朝哪个方向 利比亚军方总参谋长在土耳其坠机事故中身亡 武契奇 ...

A Baltimore jury ordered Johnson & Johnson and its subsidiaries to pay over $1.5 billion to a woman who claimed decades of exposure to asbestos in the company’s talc-based products caused her peritoneal mesothelioma, a form of cancer.Jurors in the Circuit Court for Baltimore City, Md., on Monday found the company, two of its subsidiaries and spinoff Kenvue liable for failing to warn plaintiff Cherie Craft that its baby powder contained asbestos.Johnson & Johnson said it will appeal the jury’s decision, whic ...

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Tuesday's key moments. 1. Stocks were little changed as bond yields rose after a strong third-quarter GDP reading dampened expectations for future Fed interest rate cuts. However, Jim Cramer said the market is not right because once President Donald Trump gets his Fed chief in place, they will be at Trump's behest to cut rates. The president has made no secret that he wants rates wa ...

Key Takeaways The EC approved Tremfya for patients aged 6-17 years with plaque psoriasis needing systemic therapy.The PROTOSTAR study met PASI 75 and IGA 0/1 endpoints at 16 weeks.Tremfya drove JNJ sales growth, generating $3.6B in the first nine months of 2025, up 31% year over year.Johnson & Johnson (JNJ) announced that the European Commission (EC) has approved an expanded use of its blockbuster psoriasis drug, Tremfya, in children. Tremfya is now approved to treat pediatric and adolescent patients (aged ...

Key Takeaways TPB relies on habitual consumer products, helping support steadier demand during economic slowdowns.JNJ benefits from non-discretionary healthcare demand and a diversified pharma and medical tech portfolio.NEE blends regulated utility stability with long-term growth from renewables and energy infrastructure.As investors look ahead to 2026, caution is gradually replacing confidence. After an extended period of market strength, supported by innovation-led growth and steady consumer activity, exp ...

Industry Overview - The drug and biotech sector has shown recovery after a weak first half, with large drugmakers signing pricing agreements with the Trump administration [1] - Dealmaking activity surged in the second half, boosting investor confidence, with the Large Cap Pharmaceuticals industry outperforming the S&P 500 in the past three months [1][4] - Innovation is at its peak, particularly in areas like obesity, cell and gene therapy, and next-gen oncology treatments, attracting investor attention [2] - Despite headwinds such as pipeline setbacks and regulatory risks, the outlook for growth in 2026 remains favorable due to rapid innovation and increased use of AI in drug development [2] Eli Lilly - Eli Lilly has achieved significant success with its tirzepatide medicines, including diabetes drug Mounjaro and weight loss medicine Zepbound, which are key revenue drivers [6][7] - Strong sales growth in 2025 is attributed to international market launches and improved production, with continued demand expected in 2026 [7] - Lilly is investing in obesity treatments with new molecules in clinical development, including orforglipron and retatrutide, with regulatory applications filed for orforglipron [8][9] - Despite challenges like declining product prices and competition in the GLP-1 market, Lilly's stock has risen 39.3% year to date, with 2026 earnings estimates improving from $30.78 to $33.61 per share [10] Johnson & Johnson - J&J has shown strong operational performance in 2025, with double-digit revenue growth from key brands despite the loss of exclusivity for Stelara [11] - The Innovative Medicine segment is expected to accelerate growth in 2026, driven by key products and new launches [12] - J&J's MedTech business has improved, with growth driven by acquired cardiovascular businesses and new product launches expected to contribute to 2026 growth [13][14] - The company has advanced its pipeline significantly and is on an acquisition spree, with a Zacks Rank of 2 (Buy) and a stock rise of 43.3% year to date [17] AbbVie - AbbVie faces declining sales from Humira due to loss of exclusivity but has successfully launched new immunology medicines Skyrizi and Rinvoq, generating combined sales of $18.5 billion in the first nine months of 2025 [18][19] - Strong market growth and new indications for these drugs are expected to drive future growth, alongside contributions from newer drugs [20] - AbbVie anticipates a high single-digit CAGR through 2029, supported by robust performance from Skyrizi and Rinvoq, with a Zacks Rank of 3 and a stock rise of 28.2% year to date [21][22] Amgen - Amgen's revenue growth is driven by key medicines like Repatha and new biosimilars, compensating for declines from mature drugs [23][24] - The company is focusing on obesity treatments with its candidate MariTide, which differentiates itself with a convenient dosing method [24] - Amgen's stock has risen 27.3% year to date, with 2026 earnings estimates increasing from $21.43 to $21.62 per share [25] AstraZeneca - AstraZeneca has several blockbuster drugs exceeding $1 billion in sales, with newer products contributing to growth despite losses from mature brands [26][27] - The company expects to achieve industry-leading top-line growth through 2030, with plans to launch 20 new medicines and generate $80 billion in total revenues [28] - AstraZeneca faces challenges such as competition and regulatory impacts but maintains a stable earnings estimate of $5.15 per share for 2026, with a stock rise of 10.7% year to date [29][30]

alengo / E+ via Getty Images One question about how likely a company is to raise its dividend next year is whether it has already raised it for decades. If one is willing to posit that, several companies are likely candidates. 24/7 Wall St. Key Points These four companies have increased their dividends annually for decades. And they will mostly likely boost their payouts again in the coming year. If you’re thinking about retiring or know someone who is, there are three quick questions causing many ...

Core Insights - Dividend Kings are companies that have increased their dividend payments for at least 50 consecutive years, providing a reliable long-term investment strategy [1] - Several Dividend Kings, including Coca-Cola, Johnson & Johnson, and Consolidated Edison, have achieved over 100% total return in the past decade, suggesting a potential for doubling investments in the next 10 years through a buy-and-hold strategy [1] Group 1: Coca-Cola - Coca-Cola increased its dividend payment by 5.2% this year, marking its 63rd consecutive year of dividend growth [3] - The company has delivered a total return of approximately 125% over the past decade, equating to an annualized return of 8.4% [3][4] - Coca-Cola aims for organic revenue growth of 4% to 6% per year and high-single-digit earnings-per-share growth, supported by a strong balance sheet and significant investments in product innovation and marketing [4][5] Group 2: Johnson & Johnson - Johnson & Johnson raised its dividend payment by 4.8% this year, also extending its dividend growth streak to 63 years [6] - The company has achieved a total return exceeding 165% over the past decade, with an annualized return of 10.3% [6] - Johnson & Johnson holds a AAA bond rating, indicating a strong financial profile, and consistently produces resilient earnings [8]